Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01415921 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Pyridostigmine in Heart Failure
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT01415921 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 33 participants.
The verdict
NCT01415921, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
Heart failure, a common heart disease affecting nearly 6 million Americans, is associated with high rates of hospitalization and death. Abnormalities in the autonomic nervous system are thought to play an important role in the progression of heart failure. This proposal aims to determine whether novel application of pyridostigmine, a drug currently approved by the FDA only for the treatment of neuromuscular disease, can improve autonomic nervous system function in heart failure patients.
Interventions
- DRUG Pyridostigmine Bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01415921
The ClinicalTrials.gov registry entry for NCT01415921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pyridostigmine Bromide is the first listed.
NCT01415921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01415921 about?
NCT01415921 is a clinical study titled "Safety Study of Pyridostigmine in Heart Failure". Heart failure, a common heart disease affecting nearly 6 million Americans, is associated with high rates of hospitalization and death. Abnormalities in the autonomic nervous system are thought to play an important role in the progression of heart failure. This proposal aims to determine whether nov...
What is the current status of trial NCT01415921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2011-10. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01415921?
The interventions under investigation include: Pyridostigmine Bromide (DRUG).
Who is sponsoring clinical trial NCT01415921?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.